US Patent

US7598279 — Neurotherapeutic azole compounds

Composition of Matter · Assigned to SK Holdings Co Ltd · Expires 2032-10-30 · 6y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of azole compounds containing a carbamoyl group and their pharmaceutically useful salts, used as anticonvulsants.

USPTO Abstract

Azole compounds containing carbamoyl group and pharmaceutically useful salts thereof are described. The compounds are effective anticonvulsants which are used in the treatment of disorders of the central nervous system, especially as anxiety, depression, convulsion, epilepsy, migraine, bipolar disorder, drug abuse, smoking, ADHD, obesity, sleep disorder, neuropathic pain, stroke, cognitive impairment, neurodegeneration, stroke and muscle spasm.

Drugs covered by this patent

Patent Metadata

Patent number
US7598279
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-10-30
Drug substance claim
Yes
Drug product claim
No
Assignee
SK Holdings Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.